Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations
INGELHEIM, Germany -- (BUSINESS WIRE) -- Boehringer Ingelheim today announced final results from RE-VERSE AD™.1,2 The study shows that Praxbind® (idarucizumab) was able to immediately and compl......

